Purpose
=======

The CARRAnet Registry, a multicenter registry of children with rheumatic diseases in the U.S. organized by the Childhood Arthritis Rheumatology and Research Alliance (CARRA), began enrollment in May 2010. Our aims were to describe the characteristics of children with JIA enrolled into the registry to date and to identify characteristics associated with the use of biologic disease-modifying anti-rheumatic drugs (DMARDs).

Methods
=======

Data were extracted for all children with JIA who were enrolled up to December 28, 2010. Children who had ever received biologic DMARDs were compared to children who had not using relative risks (RR) and unpaired t-tests.

Results
=======

1072 children with JIA were enrolled during the first 7 months by 26 centers. The categorical characteristics of the cohort are shown in Table [1](#T1){ref-type="table"} and the continuous characteristics of the cohort are shown in Table [2](#T2){ref-type="table"}. 77% had received at least one non-biologic DMARD at enrollment, most commonly methotrexate. 69% had received corticosteroids during their disease course, most frequently intra-articular (49%) and daily oral (36%). 45% of the cohort received one or more biologic DMARD during their disease course. The proportion of patients who received specific biologic agents is shown in Table [3](#T3){ref-type="table"}. Children receiving biologic DMARDs were older at enrollment (mean age 13 years versus 10 years; p \<0.001) and had a longer disease duration (mean 6 years versus 4 years; p\<0.001). Children with imaging evidence of joint damage (RR 1.6; 95% CI: 1.3-1.9), positive RF (RR: 1.36; 95% CI 1.1 -- 1.6), or positive anti-CCP (RR: 1.35; 1.1-1.7) were more likely to have received a biologic DMARD. Children with oligoarthritis were less likely to have received a biologic DMARD than other categories.

  Characteristuc                        N (%)
  ------------------------------------- ----------
  *JIA Category*                        
  Systemic                              87 (8)
  Polyarticular (RF-)                   334 (31)
  Polyarticular (RF+)                   266 (25)
  Extended Oligoarticular               91 (9)
  Psoriatic                             56 (5)
  Enthesitis-Related                    110 (10)
  Undifferentiated                      37 (3)
  Other or unknown                      14 (1)
  *Female*                              783 (73)
  *Race*                                
  White                                 965 (89)
  Black or African American             62 (6)
  Asian                                 29 (3)
  Other                                 54 (5)
  *Ethnicity*                           
  Hispanic or Latino                    101 (9)
                                        
  *Positic Serology*                    
  ANA                                   483 (45)
  RF (initial)                          88 (8)
  RF (confirmatory)                     46 (4)
  Anti-CCP                              51 (5)
  HLA-B27                               95 (9)
                                        
  *Uveitis*                             
  Current                               46 (4)
  Past                                  74 (7)
                                        
  *ACR Functional Class*                
  Class I                               872 (81)
  Class II                              179 (17)
  Class III                             28 (3)
  Class IV                              4 (\<1)
                                        
  *Health-related quality of life*      
  Excellent                             242 (23)
  Very good                             437 (41)
  Good                                  352 (33)
  Poor                                  28 (3)
  Very Poor                             1 (\<1)
  *Imaging evidence of joint damageI*   265 (25)

  Characteristic                                                        Mean (Median)   Range
  --------------------------------------------------------------------- --------------- -----------
  Age at enrollment (years)                                             11 (12)         \<1 -- 22
                                                                                        
  Age at symptom onset (years)                                          7 (5)           \<1 -- 16
                                                                                        
  Age at first rheumatology visit (years)                               7 (7)           \<1 -- 21
                                                                                        
  Disease duration (years)                                              5 (4)           0 -- 18
                                                                                        
  Duration between sympton onset and first rheumatology visit (years)   1 (\<1)         0 -- 12
                                                                                        
  Number of active joints                                               2 (0)           0 -- 38
  Physician global assessment of disease activity                       2 (1)           0 -- 9
  Parent/patient assessment of disease acticity                         2 (1)           0 - 10
  Parent/patient assessment of overall well-being                       2 (2)           0 -- 9
  Patrent/patient asessment of pain                                     3 (2)           0 -- 10
  CHAQ score                                                            0.35 (0.125)    0 -- 3

  Biologic medication       Current use               Prior use
  ------------------------- ------------------------- -------------------------
                            N (% of biologic users)   N (% of biologic users)
                                                      
  *TNF-alpha inhibitirs*                              
  Adalimumab                78 (7)                    70 (6)
  Cartolizumab              4 (\<1)                   0
  Etanercept                214 (20)                  183 (17)
  Gollimumab                5 (\<1)                   4 (\<1)
  Inflximab                 46 (4)                    46 (4)
  *IL-1 Inhibitors*                                   
  Ankira                    14 (1)                    22 (2)
  Rilonacept                2 (\<1)                   2 (\<1)
  *Other biologic agents*                             
  Abatacept                 24 (2)                    8 (\<1)
  Rituximab                 2 (\<1)                   8 (\<1)
  Tocilizumab               6 (\<1)                   0 (\<1)

Conclusion
==========

The majority of patients with JIA enrolled into the CARRAnet registry has relatively low disease activity, minimal disability, and have received at least one DMARD. Positive anti-CCP or RF, joint damage on imaging, older age at enrollment and longer disease duration were associated with biologic DMARD use. Limitations include the underrepresentation of non-English speaking families and enrollment bias. Continued enrollment into this cohort will support future analyses with increased sample sizes and the potential for longitudinal data analysis.
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